Meningococcal polysaccharide serogroups a, c, w-135 and y conjugate vaccine
Brand: MenQuadfi
PBAC's latest decision on Meningococcal polysaccharide serogroups a, c, w-135 and y conjugate vaccine: Recommended (2020). Considered for Prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W-135, and Y in children aged 12 months, adolescents aged 14–19 years, and medically at-risk individuals aged ≥12 months (those with asplenia, complement deficiency, or undergoing eculizumab treatment).
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2020
Submissions
1
2020 → 2020
Eligible population
Children aged 12 months; adolescents aged 14–19 years; medically at-risk subjects aged ≥12 months with congenital or acquired asplenia, complement deficiency, or undergoing eculizumab treatment.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Seroresponse rate (hSBA antibody titre ≥1:8)
Pivotal trial size
3,815 patients
Key trials
MET51, MET54, MET50, MET57, MET43, MET56
Comparator
Nimenrix (meningococcal serogroup A, C, W-135 and Y tetanus toxoid conjugate vaccine)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. Submission based on cost-minimisation versus Nimenrix.